ZOM Share Price | Zomedica Corp. Stock Analysis & Recommendation

Q: How big is Zomedica Corp.?

Market Cap: As of Jun 18, Zomedica Corp. has a market capitalization of 41.65 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Zomedica Corp. reported net sales of 27.53 million and a net profit of -101.63 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 195.66 million and total assets of 207.36 million.

Q: What does Zomedica Corp. do?

Overview: Zomedica Corp. is a development stage veterinary diagnostic and pharmaceutical company focused on developing products for companion animals within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -64 Million (Quarterly Results - Mar 2025) Market-cap: USD 41.65 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.48 Return on Equity: -22.48% Price to Book: 0.31 Contact Details: Address: 100 Phoenix Drive, Suite 180, ANN ARBOR MI: 48108 Tel: 1 734 3692555 Website: http://www.zomedica.com/

Q: Who are in the management team of Zomedica Corp.?

As of March 2022, the management team of Zomedica Corp. includes the following individuals:- Mr. Jeffrey Rowe, Chairman of the Board- Mr. Robert Cohen, Chief Executive Officer and Director- Dr. William MacArthur, Executive Member and Chief Medical Officer, Director of Research and Development- Mr. Christopher Wolfenberg, Director- Dr. Jane Eagleson, Independent Director- Christopher MacLeod, Independent Director- Dr. Johnny Powers, Independent Director- Mr. Thomas Robitaille, Independent DirectorThis team is responsible for guiding the company's strategic direction and operations.

Q: Is Zomedica Corp. overvalued or undervalued?

As of 1 March 2022, Zomedica Corp. has moved from a "does not qualify" rating to "risky." The company appears to be overvalued given its current metrics. Key valuation ratios include a Price to Book Value of 0.33, an EV to EBIT of 0.58, and an EV to EBITDA of 0.77, all indicating a lack of profitability and financial stability. In comparison to its peers, Zomedica's P/E ratio is -2.71, while Fusion Pharmaceuticals, Inc. has a P/E of -17.58, and Gossamer Bio, Inc. has a P/E of -4.38, suggesting that Zomedica is not the worst performer in its group but still reflects significant risk. The recent stock performance comparison with the S&P 500 is not available, yet the overall valuation metrics reinforce the notion of Zomedica being overvalued in its current state.

Q: Is Zomedica Corp. technically bullish or bearish?

As of 12 September 2025, the technical trend for Zomedica Corp. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD and KST are mildly bullish, while the monthly KST is bearish. The RSI is bullish on the weekly timeframe but shows no signal monthly. Moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, the Bollinger Bands reflect a mildly bullish stance weekly but a mildly bearish one monthly. In terms of performance, Zomedica has underperformed the S&P 500 across multiple periods, with a 1-week return of -26.68% compared to the S&P's 1.05%, and a 1-year return of -34.04% versus the S&P's 17.14%.

Results Declared: Zomedica Corp. has declared results on 06 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

912.0 k

Shareholding (Dec 2025)

FII

0.86%

Held by 11 FIIs

DII

93.11%

Held by 16 DIIs

Promoter

0.00%

How big is Zomedica Corp.?

22-Jun-2025

As of Jun 18, Zomedica Corp. has a market capitalization of 41.65 million, with net sales of 27.53 million and a net profit of -101.63 million over the latest four quarters. As of December 2024, the company reported shareholder's funds of 195.66 million and total assets of 207.36 million.

View full answer

What does Zomedica Corp. do?

22-Jun-2025

Zomedica Corp. is a veterinary diagnostic and pharmaceutical company focused on companion animals, with recent quarterly net sales of $7 million and a net loss of $64 million. The company has a market cap of $41.65 million and no dividend yield.

View full answer

Who are in the management team of Zomedica Corp.?

22-Jun-2025

As of March 2022, Zomedica Corp.'s management team includes Chairman Jeffrey Rowe, CEO Robert Cohen, Chief Medical Officer Dr. William MacArthur, and several independent directors, including Dr. Jane Eagleson and Dr. Johnny Powers, among others. They oversee the company's strategic direction and operations.

View full answer

Is Zomedica Corp. overvalued or undervalued?

20-Sep-2025

As of March 1, 2022, Zomedica Corp. is rated as "risky" and appears overvalued with key metrics indicating a lack of profitability, including a Price to Book Value of 0.33 and a P/E ratio of -2.71, suggesting significant risk compared to its peers.

View full answer

Is Zomedica Corp. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Zomedica Corp.'s technical trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, while underperforming the S&P 500 with a 1-week return of -26.68% and a 1-year return of -34.04%.

View full answer

Compare Zomedica Corp. with Similar Stocks

Sagimet Biosciences, Inc.Emergent BioSolutions, Inc.Fusion Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 125 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.44

Return on Equity

-23.97%

Price to Book

1.04

Revenue and Profits:

Net Sales:

9 Million

(Quarterly Results - Mar 2026)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-30.74%

6 Months

69.52%

1 Year

120.21%

2 Years

-20.89%

3 Years

-50.81%

4 Years

-65.12%

5 Years

-90.55%

Zomedica Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

98.02%

EBIT Growth (5y)

-151.11%

EBIT to Interest (avg)

-27.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.48

Sales to Capital Employed (avg)

0.15

Tax Ratio

0.44%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

10.94%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.04

EV to EBIT

-2.30

EV to EBITDA

-3.10

EV to Capital Employed

1.08

EV to Sales

2.46

PEG Ratio

Dividend Yield

ROCE (Latest)

-46.85%

ROE (Latest)

-23.97%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (6.03%)

Foreign Institutions

Held by 11 Foreign Institutions (0.86%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 35.38% vs 3.17% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 92.95% vs -593.48% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.80",
          "val2": "6.50",
          "chgp": "35.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.00",
          "val2": "-6.50",
          "chgp": "53.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-55.80",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.50",
          "val2": "-63.80",
          "chgp": "92.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-556.90%",
          "val2": "-1,340.80%",
          "chgp": "78.39%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 17.22% vs 8.33% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -74.26% vs -36.23% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.00",
          "val2": "27.30",
          "chgp": "17.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.60",
          "val2": "-27.00",
          "chgp": "23.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-55.80",
          "val2": "-16.00",
          "chgp": "-248.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-81.90",
          "val2": "-47.00",
          "chgp": "-74.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-890.40%",
          "val2": "-1,283.80%",
          "chgp": "39.34%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

8.80

6.50

35.38%

Operating Profit (PBDIT) excl Other Income

-3.00

-6.50

53.85%

Interest

0.00

Exceptional Items

0.00

-55.80

100.00%

Consolidate Net Profit

-4.50

-63.80

92.95%

Operating Profit Margin (Excl OI)

-556.90%

-1,340.80%

78.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 35.38% vs 3.17% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 92.95% vs -593.48% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

32.00

27.30

17.22%

Operating Profit (PBDIT) excl Other Income

-20.60

-27.00

23.70%

Interest

0.00

Exceptional Items

-55.80

-16.00

-248.75%

Consolidate Net Profit

-81.90

-47.00

-74.26%

Operating Profit Margin (Excl OI)

-890.40%

-1,283.80%

39.34%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 17.22% vs 8.33% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -74.26% vs -36.23% in Dec 2024

All Annual Results

Company CV

About Zomedica Corp.

Zomedica Corp.

Pharmaceuticals & Biotechnology

Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.

Company Coordinates

Company Details

100 Phoenix Drive, Suite 180 , ANN ARBOR MI : 48108

Tel: 1 734 3692555

http://www.zomedica.com/

Registrar Details